強力な非ペプチドMDM2阻害剤の構造ベースの設計
Ke Ding1, Yipin Lu, Zaneta Nikolovska-Coleska
1Departments of Internal Medicine and Medicinal Chemistry and Comprehensive Cancer Center, and Life Sciences Institute, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA.
Journal of the American Chemical Society
|July 21, 2005
まとめ
研究者らは,p53-MDM2相互作用を標的とした強力な非ペプチド小分子阻害剤を設計した. 化合物1dは,正常な細胞に対する最小限の毒性で前立腺がん細胞の成長を効果的に抑制します.
科学分野:
- 薬用化学 薬用化学について
- 化学生物学 化学生物学とは
- ドラッグ・デザイン・ドラッグ・デザイン
背景:
- p53-MDM2のタンパク質とタンパク質の相互作用は,がん治療の重要な標的である.
- タンパク質とタンパク質の相互作用のための非ペプチド小分子阻害剤の開発は困難です.
研究 の 目的:
- p53-MDM2相互作用を標的とした新しい非ペプチド小分子阻害剤の構造ベースの設計について報告する.
- がん細胞におけるこれらの阻害剤の効能と選択性を評価する.
主な方法:
- 構造に基づく薬物設計アプローチ.
- 非ペプチド小分子の合成と特徴付け.
- 結合親和度 (Ki) を決定する生化学的測定法.
- 細胞ベースの測定法で,細胞成長の抑制と毒性を評価する.
主要な成果:
- 非ペプチド小分子MDM2阻害剤のクラスが成功裏に設計されました.
- 最も強力な化合物である1dは,キ値86nMを示し,天然のp53ペプチドの効力を大幅に上回った.
- 化合物1dは,LNCaP前立腺がん細胞成長 (ワイルド型p53) の強力な阻害を示し,PC-3細胞に対する活動が最小限であった (p53は削除された).
- 化合物1dは,正常な前立腺上皮細胞に対する最小限の毒性を示した.
結論:
- 構造ベースの設計は,タンパク質とタンパク質の相互作用に挑戦する強力な,細胞に浸透する,非ペプチド阻害剤を開発するための実行可能な戦略です.
- 化合物1dは,p53-MDM2-依存がんに対する新しい治療法の開発に有望なリードを示しています.
- 開発された阻害剤は,安全性プロファイルが好ましい潜在的な治療手段を提供します.
関連する概念動画
01:25Drug-Receptor Bonds
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...